NTM Infections: Expanding Treatment Access

Track the trends in DCM & more—explore the data visually!: Click Here

NTM Infections Epidemiological Segmentation
The epidemiological segmentation of NTM infections in the 7MM from 2020 to 2034 covers:

Total prevalent cases
Total diagnosed prevalent cases
Gender-specific cases
Species-specific cases
Type-specific cases
Severity-specific cases

NTM Infections Epidemiology
In 2023, the prevalence of NTM infections across the 7MM exhibited distinct trends:

In the US, approximately 108,000 diagnosed prevalent cases were reported.
Of these cases, 68% were female, and 32% were male.
Among the diagnosed cases, 86,000 were pulmonary NTM infections, while 22,000 were extrapulmonary.

Break down the numbers. Understand the strategy. Download the report: Click Here

NTM Infections Market
The US market size for NTM infections was estimated to be around USD 360 million in 2023.

NTM Infections Market Drivers
The introduction of emerging therapies such as Epetraborole, MNKD-101, and SPR720 is anticipated to significantly enhance the treatment landscape by targeting specific NTM species with improved efficacy and safety.

Increased awareness of NTM infections and advances in diagnostic technologies are facilitating earlier diagnosis, improving disease management, and driving market growth.

NTM Infections Market Barriers
The diversity of NTM species and their variable clinical manifestations complicate treatment approaches and clinical trial designs, making it difficult to predict treatment outcomes.

Additionally, high treatment costs and limited access—particularly in underserved areas—remain major challenges to market expansion.

NTM Infections Emerging Therapies